Annovis Bio, Inc.

Annovis Bio, Inc.

Biotechnology • Healthcare • Malvern, PA, United States • ANVS (NYQ)

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer's disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.

484 875 3192 101 Lindenwood Drive, Malvern, PA 19355, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Annovis Bio Stock (ANVS) Opinions on Phase 3 Alzheimer’s Trial Progress - Quiver Quantitative
Quiver Quantitative • Nov 12
Annovis Bio director Hoffman buys $159k in shares - Investing.com
Investing.com • Nov 25
Director Makes Bold Move with Major Annovis Bio Stock Purchase - TipRanks
TipRanks • Nov 25
Annovis Announces $6 Million Registered Direct Offering of Common Stock - Yahoo Finance
Yahoo Finance • Oct 10
Annovis Bio Stock Jumps On Heels Of New Parkinson's Data - Annovis Bio (NYSE:ANVS) - Benzinga
Benzinga • Nov 17

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Annovis Bio, Inc. had layoffs?
No layoff events have been recorded for Annovis Bio, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Annovis Bio, Inc. have?
Annovis Bio, Inc. has approximately 8 employees.
What industry is Annovis Bio, Inc. in?
Annovis Bio, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Annovis Bio, Inc. a publicly traded company?
Yes, Annovis Bio, Inc. is publicly traded under the ticker symbol ANVS on the NYQ. The company has a market capitalization of approximately $0.10 billion.
Where is Annovis Bio, Inc. headquartered?
Annovis Bio, Inc. is headquartered in Malvern, PA, United States at 101 Lindenwood Drive, Malvern, PA 19355, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.